JP2009515553A - 癌の予知および予後と、癌治療のモニタリング - Google Patents

癌の予知および予後と、癌治療のモニタリング Download PDF

Info

Publication number
JP2009515553A
JP2009515553A JP2008541268A JP2008541268A JP2009515553A JP 2009515553 A JP2009515553 A JP 2009515553A JP 2008541268 A JP2008541268 A JP 2008541268A JP 2008541268 A JP2008541268 A JP 2008541268A JP 2009515553 A JP2009515553 A JP 2009515553A
Authority
JP
Japan
Prior art keywords
cancer
sample
vegf
patient
svegfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008541268A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009515553A5 (https=
Inventor
ウイルヘルム，スコット
エルティング，ジェームス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of JP2009515553A publication Critical patent/JP2009515553A/ja
Publication of JP2009515553A5 publication Critical patent/JP2009515553A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2008541268A 2005-11-14 2006-11-14 癌の予知および予後と、癌治療のモニタリング Pending JP2009515553A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73585405P 2005-11-14 2005-11-14
PCT/US2006/044117 WO2007059094A2 (en) 2005-11-14 2006-11-14 Methods for prediction and prognosis of cancer, and monitoring cancer therapy

Publications (2)

Publication Number Publication Date
JP2009515553A true JP2009515553A (ja) 2009-04-16
JP2009515553A5 JP2009515553A5 (https=) 2009-12-10

Family

ID=37814675

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008541268A Pending JP2009515553A (ja) 2005-11-14 2006-11-14 癌の予知および予後と、癌治療のモニタリング

Country Status (12)

Country Link
US (1) US20070178494A1 (https=)
EP (1) EP1963849A2 (https=)
JP (1) JP2009515553A (https=)
KR (1) KR20080073745A (https=)
CN (1) CN101454668A (https=)
AU (1) AU2006315592A1 (https=)
BR (1) BRPI0618597A2 (https=)
CA (1) CA2629860A1 (https=)
MX (1) MX2008006239A (https=)
RU (1) RU2008123406A (https=)
WO (1) WO2007059094A2 (https=)
ZA (1) ZA200804509B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014506782A (ja) * 2011-01-11 2014-03-20 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 遺伝子の発現を分析することによって患者における癌の転帰を予測するための方法
JP2014062914A (ja) * 2008-10-21 2014-04-10 Bayer Healthcare Llc 肝細胞癌と関連するシグネチャ遺伝子を利用する検査方法、及び該方法に用いられるアレイ又はキット
JP2016518837A (ja) * 2013-04-25 2016-06-30 シービーエス バイオサイエンス，カンパニー，リミテッド 肝細胞癌において分子標的治療の感受性を増加させるための分析方法

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
WO2004113274A2 (en) 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
EA010485B1 (ru) 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
SG160364A1 (en) * 2005-03-07 2010-04-29 Bayer Schering Pharma Ag Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
BRPI0617488A2 (pt) * 2005-10-21 2011-07-26 Bayer Healthcare Llc mÉtodo para a monitoraÇço do estado de uma doenÇa associada a uma via de vegf-165 ativada por ultra-expressço ou por mutaÇço de proteÍna vegf-165 em um paciente, mÉtodo de seleÇço de terapia para um paciente humano com uma doenÇa e mÉtodo de dignàstico para detectar uma doenÇa associada a uma via de vegf-165 ativada por ultra-expressço ou por mutaÇço de proteÍna vegf-165 em um paciente
CA2628091A1 (en) * 2005-11-02 2007-05-18 Bayer Healthcare Llc Methods for prediction and prognosis of cancer, and monitoring cancer therapy
US20100008910A1 (en) * 2006-09-12 2010-01-14 John Chant Methods and compositions for the diagnosis and treatment of cancer
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
US20100311106A1 (en) * 2008-01-25 2010-12-09 Hartmann Lynn C Quantitation of lobular involution for breast cancer risk prediction
GB0814722D0 (en) * 2008-08-12 2008-09-17 Ge Healthcare Ltd Treatment monitoring
EP2156834A1 (en) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye
BR112012007762A2 (pt) * 2009-10-07 2021-11-16 Koninklijke Philips Electronics Nv Método de avaliação do nível de toxicidade de um paciente que se submete a um protocolo de tratamento de câncer, produto de programa de computador, sistema (200) para avaliar o nível de toxicidade de um paciente que se submete a um protocolo de tratamento de câncer
CN102053150B (zh) * 2009-10-30 2013-07-17 上海交通大学医学院附属瑞金医院 一种人成骨肉瘤干细胞相关抗原标记物及其应用
AU2011281706A1 (en) * 2010-07-19 2013-01-10 F. Hoffmann-La Roche Ag Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
EP2601528B1 (en) * 2010-08-02 2015-10-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel methods for predicting the responsiveness of a patient affected with a tumor to a treatment with a tyrosine kinase inhibitor
WO2012081898A2 (ko) 2010-12-13 2012-06-21 사회복지법인 삼성생명공익재단 위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법
WO2013173384A1 (en) * 2012-05-16 2013-11-21 Dale Wong Method and system for sorting biological samples
EP2971101A2 (en) * 2013-03-15 2016-01-20 Janssen Pharmaceutica N.V. Assay for predictive biomarkers
RU2546035C1 (ru) * 2014-04-15 2015-04-10 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ прогнозирования развития метастазов у больных меланомой кожи
RU2643761C1 (ru) * 2017-08-10 2018-02-05 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ расчета прогноза раннего прогрессирования меланомы кожи
WO2019074920A1 (en) * 2017-10-10 2019-04-18 Oncocyte Corporation METHODS AND COMPOSITIONS FOR THE DETECTION AND DIAGNOSIS OF BREAST CANCER

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635421B1 (en) * 1997-12-09 2003-10-21 Children's Medical Center Corporation Neuropilins and use thereof in methods for diagnosis and prognosis of cancer
US20030232400A1 (en) * 2002-12-20 2003-12-18 Susan Radka Methods of screening subjects for expression of soluble receptors of vascular endothelial growth factor (VEGF) for use in managing treatment and determining prognostic outcome
WO2005009367A2 (en) * 2003-07-17 2005-02-03 Ambit Biosciences Corporation Treatment of diseases with kinase inhibitors
BRPI0508970A (pt) * 2004-03-19 2007-08-21 Penn State Res Found método combinatórios e composições para o tratamento de melanoma

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6012023020; Ｔｏｈｏｋｕ　Ｊ　Ｅｘｐ　Ｍｅｄ． Ｖｏｌ．１９５，　Ｎｏ．２, 200110, ｐ．１０１-１１３ *
JPN6012023022; Ｅｕｒｏｐｅａｎ　Ｊｏｕｒｎａｌ　ｏｆ　Ｃａｎｃｅｒ　Ｓｕｐｐｌｅｍｅｎｔｓ Ｖｏｌ．３，　Ｎｏ．２, 200510, ｐ．４２０ *
JPN6012023026; Ｐｒｏｃ　Ａｍｅｒ　Ａｓｓｏｃ　Ｃａｎｃｅｒ　Ｒｅｓ． Ｖｏｌ．４６, 200504, ｐ．１０８，　Ａｂｓｔｒａｃｔ　＃４６４ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014062914A (ja) * 2008-10-21 2014-04-10 Bayer Healthcare Llc 肝細胞癌と関連するシグネチャ遺伝子を利用する検査方法、及び該方法に用いられるアレイ又はキット
JP2014506782A (ja) * 2011-01-11 2014-03-20 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 遺伝子の発現を分析することによって患者における癌の転帰を予測するための方法
JP2017060515A (ja) * 2011-01-11 2017-03-30 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 遺伝子の発現を分析することによって患者における癌の転帰を予測するための方法
JP2016518837A (ja) * 2013-04-25 2016-06-30 シービーエス バイオサイエンス，カンパニー，リミテッド 肝細胞癌において分子標的治療の感受性を増加させるための分析方法

Also Published As

Publication number Publication date
EP1963849A2 (en) 2008-09-03
CN101454668A (zh) 2009-06-10
CA2629860A1 (en) 2007-05-24
MX2008006239A (es) 2008-12-12
WO2007059094A2 (en) 2007-05-24
ZA200804509B (en) 2009-05-27
AU2006315592A1 (en) 2007-05-24
BRPI0618597A2 (pt) 2011-09-06
US20070178494A1 (en) 2007-08-02
KR20080073745A (ko) 2008-08-11
WO2007059094A3 (en) 2008-01-24
RU2008123406A (ru) 2009-12-27

Similar Documents

Publication Publication Date Title
JP2009515553A (ja) 癌の予知および予後と、癌治療のモニタリング
US8329408B2 (en) Methods for prognosis and monitoring cancer therapy
US20040146921A1 (en) Expression profiles for colon cancer and methods of use
US20070065827A1 (en) Gene expression profiles and methods of use
US20130143762A1 (en) Gene expression profiles and methods of use
JP2007507243A (ja) 遺伝子発現プロファイルおよび使用方法
US20040191819A1 (en) Expression profiles for breast cancer and methods of use
US20070134670A1 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2011146725A1 (en) Biomarkers for a multikinase inhibitor
US20040121375A1 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2006032009A2 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2005067650A2 (en) Gene expression profiles and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091022

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091022

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120515

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121016